THE US FDA has issued warnings
to Pfizer over its lax monitoring of
physicians who are testing
experimental drugs on patients.
The problem stems from ongoing
testing of its new bipolar drug,
Geodon, of which 12 people have
so far suffered from overdoses.
According to reports, the FDA
has cracked down on Pfizer after it
found the company was not
following its own guidelines for
safely conducting the study, and
was not alerting investigators to
dosing problems as they occurred.The above article was sent to subscribers in Pharmacy Daily's issue from 21 Apr 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Apr 10
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.